# VKORC1

## Overview
The VKORC1 gene encodes the vitamin K epoxide reductase complex subunit 1, a crucial enzyme in the vitamin K cycle. This enzyme is a transmembrane protein located in the endoplasmic reticulum and is responsible for the reduction of vitamin K epoxide to vitamin K hydroquinone, a vital step for the γ-carboxylation of vitamin K-dependent proteins involved in blood coagulation and bone metabolism (Czogalla2014The; Oldenburg2006Vitamin). The VKORC1 protein's structure includes multiple transmembrane domains and conserved cysteine residues essential for its redox function (Oldenburg2006Vitamin). Genetic variations in VKORC1 can significantly impact the efficacy and safety of anticoagulant therapies, such as warfarin, by altering the enzyme's activity and sensitivity to these drugs (WATZKA2011Thirteen; BODIN2008Multiple). Understanding the function and regulation of VKORC1 is critical for optimizing anticoagulant dosing and managing associated clinical risks.

## Structure
The VKORC1 protein is an integral membrane protein located in the endoplasmic reticulum (ER) of mammalian cells. It is highly hydrophobic, which complicates its purification from native tissues (Oldenburg2006Vitamin). The protein is predicted to have a three-transmembrane topology, featuring an ER-lumenal N-terminus, three transmembrane α-helices, a large cytoplasmic loop, a small ER-lumenal loop, and a cytoplasmic C-terminus (Oldenburg2006Vitamin). However, other studies suggest a four-transmembrane helical topology, which aligns with the structure of a bacterial VKOR homolog (Shen2018Stabilization).

Key structural features include conserved cysteine residues, such as Cys132 and Cys135, which form a disulfide bond crucial for the protein's redox function (Lewis2016Warfarin; Oldenburg2006Vitamin). The protein also contains a hydrophobic sequence motif, Thr-Tyr-Ala (TYA), essential for dicoumarol binding, and mutations in this region can lead to warfarin-resistant phenotypes (Oldenburg2006Vitamin). The warfarin-binding pocket overlaps with the active site, and its stability is influenced by peripheral regions (Shen2018Stabilization). The protein's structure and function are critical for understanding its role in the vitamin K cycle and its interaction with anticoagulant drugs like warfarin (Oldenburg2006Vitamin).

## Function
VKORC1 encodes an enzyme that plays a critical role in the vitamin K cycle, which is essential for the post-translational modification of vitamin K-dependent proteins. This enzyme is responsible for the reduction of vitamin K epoxide to vitamin K hydroquinone, a necessary step for the γ-carboxylation of glutamate residues on these proteins, enabling their proper function in processes such as blood coagulation and bone metabolism (Czogalla2014The; Oldenburg2006Vitamin). 

VKORC1 is primarily active in the endoplasmic reticulum of liver cells, where it supports the synthesis of vitamin K-dependent clotting factors, crucial for hemostasis (Oldenburg2015VKORC1; Oldenburg2006Vitamin). The enzyme's activity is regulated by interactions with protein disulfide isomerase and other oxidoreductases, which provide reducing equivalents necessary for its function (Westhofen2011Human). 

In addition to its role in the vitamin K cycle, VKORC1 is involved in oxidative protein folding within the endoplasmic reticulum, suggesting an ancient evolutionary origin for its functions (Oldenburg2015VKORC1). The enzyme's activity is crucial for maintaining the balance of vitamin K in its reduced form, ensuring the proper functioning of vitamin K-dependent proteins in healthy human cells (Oldenburg2006Vitamin).

## Clinical Significance
Mutations in the VKORC1 gene are clinically significant as they can lead to resistance or sensitivity to oral anticoagulants (OACs) such as warfarin, phenprocoumon, and acenocoumarol. These drugs target the VKORC1 enzyme, which is essential for the vitamin K cycle involved in blood clotting. Genetic variations in VKORC1 can result in partial or complete resistance to these anticoagulants, necessitating higher doses to achieve therapeutic effects (WATZKA2011Thirteen; BODIN2008Multiple). Specific mutations, such as Asp36Tyr and Val66Met, have been associated with increased dosage requirements and are prevalent in certain populations (WATZKA2011Thirteen).

VKORC1 mutations can also impact bone health. Variations in this gene have been linked to differences in bone mineral density (BMD) and may influence the risk of osteoporosis by affecting the gamma-carboxylation of osteocalcin, a protein crucial for bone formation (Holzer2010Vitamin).

Additionally, VKORC1 mutations can increase the risk of bleeding complications in patients on warfarin therapy, particularly in those with conditions like Budd-Chiari syndrome. These genetic variations may alter warfarin sensitivity, leading to a higher incidence of bleeding events (Shukla2019Mutations).

## Interactions
VKORC1 interacts with several proteins and nucleic acids, playing a crucial role in the vitamin K cycle. The protein is embedded in the endoplasmic reticulum membrane and is involved in the reduction of vitamin K epoxide, which is essential for the γ-carboxylation of clotting factors (Oldenburg2006Vitamin). VKORC1's activity is influenced by its interaction with warfarin, an anticoagulant drug. Warfarin binds to VKORC1 at a site that overlaps with its active site, inhibiting its function. This interaction is stabilized by peripheral regions of the protein, which affect the sensitivity to warfarin (Shen2018Stabilization).

VKORC1 also interacts with protein disulfide isomerases, which are potential candidates for providing the reducing equivalents necessary for its activity (Oldenburg2006Vitamin). Additionally, calumenin, a soluble calcium-binding protein, has been implicated in modulating VKORC1 activity, potentially regulating its sensitivity to warfarin, although the exact mechanism remains unclear (Van2013Structural).

On the nucleic acid level, VKORC1 expression is regulated by miR-133a, a microRNA that binds to the 3′UTR of VKORC1 mRNA, reducing its expression and potentially affecting the vitamin K cycle (PérezAndreu2012miR133a). This interaction highlights the role of miRNAs in the post-transcriptional regulation of VKORC1.


## References


[1. (Czogalla2014The) Katrin J. Czogalla, Arijit Biswas, Simone Rost, Matthias Watzka, and Johannes Oldenburg. The arg98trp mutation in human vkorc1 causing vkcfd2 disrupts a di-arginine–based er retention motif. Blood, 124(8):1354–1362, August 2014. URL: http://dx.doi.org/10.1182/blood-2013-12-545988, doi:10.1182/blood-2013-12-545988. This article has 16 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2013-12-545988)

[2. (Holzer2010Vitamin) Gerold Holzer, Anna Verena Grasse, Sonja Zehetmayer, Peter Bencur, Christian Bieglmayer, and Christine Mannhalter. Vitamin k epoxide reductase (vkorc1) gene mutations in osteoporosis: a pilot study. Translational Research, 156(1):37–44, July 2010. URL: http://dx.doi.org/10.1016/j.trsl.2010.05.005, doi:10.1016/j.trsl.2010.05.005. This article has 10 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.trsl.2010.05.005)

[3. (Westhofen2011Human) Philipp Westhofen, Matthias Watzka, Milka Marinova, Moritz Hass, Gregor Kirfel, Jens Müller, Carville G. Bevans, Clemens R. Müller, and Johannes Oldenburg. Human vitamin k 2,3-epoxide reductase complex subunit 1-like 1 (vkorc1l1) mediates vitamin k-dependent intracellular antioxidant function. Journal of Biological Chemistry, 286(17):15085–15094, April 2011. URL: http://dx.doi.org/10.1074/jbc.M110.210971, doi:10.1074/jbc.m110.210971. This article has 118 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M110.210971)

[4. (Oldenburg2015VKORC1) Johannes Oldenburg, Matthias Watzka, and Carville Bevans. Vkorc1 and vkorc1l1: why do vertebrates have two vitamin k 2,3-epoxide reductases? Nutrients, 7(8):6250–6280, July 2015. URL: http://dx.doi.org/10.3390/nu7085280, doi:10.3390/nu7085280. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/nu7085280)

[5. (PérezAndreu2012miR133a) Virginia Pérez-Andreu, Raúl Teruel, Javier Corral, Vanessa Roldán, Nuria García-Barberá, Salam Salloum-Asfar, María José Gómez-Lechón, Stephane Bourgeois, Panos Deloukas, Mia Wadelius, Vicente Vicente, Rocío González-Conejero, and Constantino Martínez. Mir-133a regulates vitamin k 2,3-epoxide reductase complex subunit 1 (vkorc1), a key protein in the vitamin k cycle. Molecular Medicine, 18(11):1466–1472, November 2012. URL: http://dx.doi.org/10.2119/molmed.2012.00062, doi:10.2119/molmed.2012.00062. This article has 32 citations and is from a peer-reviewed journal.](https://doi.org/10.2119/molmed.2012.00062)

[6. (WATZKA2011Thirteen) M. WATZKA, C. GEISEN, C.G. BEVANS, K. SITTINGER, G. SPOHN, S. ROST, E. SEIFRIED, C.R. MÜLLER, and J. OLDENBURG. Thirteen novel vkorc1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. Journal of Thrombosis and Haemostasis, 9(1):109–118, January 2011. URL: http://dx.doi.org/10.1111/j.1538-7836.2010.04095.x, doi:10.1111/j.1538-7836.2010.04095.x. This article has 79 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/j.1538-7836.2010.04095.x)

[7. (Shen2018Stabilization) G. Shen, S. Li, W. Cui, S. Liu, Q. Liu, Y. Yang, M. Gross, and W. Li. Stabilization of warfarin‐binding pocket of vkorc1 and vkorl1 by a peripheral region determines their different sensitivity to warfarin inhibition. Journal of Thrombosis and Haemostasis, 16(6):1164–1175, June 2018. URL: http://dx.doi.org/10.1111/jth.14127, doi:10.1111/jth.14127. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/jth.14127)

[8. (Van2013Structural) Wade D. Van Horn. Structural and functional insights into human vitamin k epoxide reductase and vitamin k epoxide reductase-like1. Critical Reviews in Biochemistry and Molecular Biology, 48(4):357–372, April 2013. URL: http://dx.doi.org/10.3109/10409238.2013.791659, doi:10.3109/10409238.2013.791659. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.3109/10409238.2013.791659)

[9. (Oldenburg2006Vitamin) Johannes Oldenburg, Carville G. Bevans, Clemens R. Müller, and Matthias Watzka. Vitamin k epoxide reductase complex subunit 1 (vkorc1): the key protein of the vitamin k cycle. Antioxidants &amp; Redox Signaling, 8(3–4):347–353, March 2006. URL: http://dx.doi.org/10.1089/ars.2006.8.347, doi:10.1089/ars.2006.8.347. This article has 81 citations.](https://doi.org/10.1089/ars.2006.8.347)

[10. (Lewis2016Warfarin) Benjamin C. Lewis, Pramod C. Nair, Subash S. Heran, Andrew A. Somogyi, Jeffrey J. Bowden, Matthew P. Doogue, and John O. Miners. Warfarin resistance associated with genetic polymorphism of vkorc1: linking clinical response to molecular mechanism using computational modeling. Pharmacogenetics and Genomics, 26(1):44–50, January 2016. URL: http://dx.doi.org/10.1097/FPC.0000000000000184, doi:10.1097/fpc.0000000000000184. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/FPC.0000000000000184)

[11. (Shukla2019Mutations) Akash Shukla, Abhinav Jain, Vinit Kahalekar, Sheetal Bendkhale, Nithya Gogtay, Urmila Thatte, and Shobna Bhatia. Mutations in cyp2c9 and/or vkorc1 haplotype are associated with higher bleeding complications in patients with budd–chiari syndrome on warfarin. Hepatology International, 13(2):214–221, January 2019. URL: http://dx.doi.org/10.1007/s12072-018-9922-6, doi:10.1007/s12072-018-9922-6. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12072-018-9922-6)

[12. (BODIN2008Multiple) L. BODIN, J. PERDU, M. DIRY, M.H. HORELLOU, and M.A. LORIOT. Multiple genetic alterations in vitamin k epoxide reductase complex subunit 1 gene (vkorc1) can explain the high dose requirement during oral anticoagulation in humans. Journal of Thrombosis and Haemostasis, 6(8):1436–1439, August 2008. URL: http://dx.doi.org/10.1111/j.1538-7836.2008.03049.x, doi:10.1111/j.1538-7836.2008.03049.x. This article has 32 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/j.1538-7836.2008.03049.x)